EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II)

• Main Authors: E. L. Nasonov, A. S. Avdeeva, A. M. Lila
• Format: Article
• Language: Russian
• Published: IMA-PRESS LLC 2020-04-01
• Series: Научно-практическая ревматология
• Subjects: jak inhibitors; tofacitinib; immune-mediated inflammatory rheumatic diseases
• Online Access: https://rsp.mediar-press.net/rsp/article/view/2880

The design of targeted oral anti-inflammatory drugs, such as Janus kinase (JAK) inhibitors, the first representative of which is tofacitinib (TOFA), is considered a major achievement in biology and medicine early in the 21st century. Part I of the review considers the materials of studies evaluating the efficacy and safety of TOFA in rheumatoid arthritis (RA). The expansion of ideas about the mechanisms of development  and chronicity of inflammation and the antiinflammatory and immunomodulatory effects of TOFA using a  RA model has created theoretical and clinical prerequisites for studying the efficacy of TOFA in other  immune-mediated inflammatory rheumatic diseases (IMIRDs) and chronic inflammatory non-rheumatic diseases. Part II of the review summarizes new data that allow one to formulate main areas of further clinical and fundamental studies, the objective of which is to expand indications for and to personalize therapy with JAK inhibitors in patients with IMIRDs.